Abstract
The overall pharmaceutical market is changing. A more personalised medicine approach is replacing the concept of blockbuster drugs and the “one size fits all” model. The two main forces that fuel the growth of nano-enabled drug technologies are the low aqueous solubility of new chemical entities and the pharmaceutical market itself, as the development of novel drug delivery systems can extend the drug patent lifetime. Classical solubilisation techniques, such as salt formation and the use of cyclodextrins can only be applied to drugs with ionisable groups or specific molecular weight ranges in order to fit in the cavity of the cyclodextrin. However, drug nanonisation, or particle size reduction into the nanosize range, is a versatile technique that can be applied to a wide range of pharmaceutical compounds. Nano-drugs exhibit higher surface area per unit of volume, which leads to faster dissolution kinetics and hence potentially improved bioavailability. Marketed nano-drugs are mostly crystalline due to the improved physical stability afforded by the crystalline state whereas amorphous nano-drugs have been largely neglected in spite of generating higher saturation solubility compared to their crystalline counterparts. Due to the vast potential in the global pharmaceutical market, many technologies have been licensed to produce nano-drugs. Among them, the most successful by far is Nanocrystal® Technology based on wet milling methods. In this review, the main methods to generate and characterise nano-drugs are covered and also, the biopharmaceutical characteristics of the marketed nano-drugs are discussed.
Keywords: Amorphous, Bioavailability, Crystalline, Nanomaterials, Nanoparticles, Stability, Nanocrystal, Nanoamorphous.
Current Topics in Medicinal Chemistry
Title:Emerging Nanonisation Technologies: Tailoring Crystalline Versus Amorphous Nanomaterials
Volume: 15 Issue: 22
Author(s): Dolores R. Serrano, Kieran H. Gallagher and Anne Marie Healy
Affiliation:
Keywords: Amorphous, Bioavailability, Crystalline, Nanomaterials, Nanoparticles, Stability, Nanocrystal, Nanoamorphous.
Abstract: The overall pharmaceutical market is changing. A more personalised medicine approach is replacing the concept of blockbuster drugs and the “one size fits all” model. The two main forces that fuel the growth of nano-enabled drug technologies are the low aqueous solubility of new chemical entities and the pharmaceutical market itself, as the development of novel drug delivery systems can extend the drug patent lifetime. Classical solubilisation techniques, such as salt formation and the use of cyclodextrins can only be applied to drugs with ionisable groups or specific molecular weight ranges in order to fit in the cavity of the cyclodextrin. However, drug nanonisation, or particle size reduction into the nanosize range, is a versatile technique that can be applied to a wide range of pharmaceutical compounds. Nano-drugs exhibit higher surface area per unit of volume, which leads to faster dissolution kinetics and hence potentially improved bioavailability. Marketed nano-drugs are mostly crystalline due to the improved physical stability afforded by the crystalline state whereas amorphous nano-drugs have been largely neglected in spite of generating higher saturation solubility compared to their crystalline counterparts. Due to the vast potential in the global pharmaceutical market, many technologies have been licensed to produce nano-drugs. Among them, the most successful by far is Nanocrystal® Technology based on wet milling methods. In this review, the main methods to generate and characterise nano-drugs are covered and also, the biopharmaceutical characteristics of the marketed nano-drugs are discussed.
Export Options
About this article
Cite this article as:
Serrano R. Dolores, Gallagher H. Kieran and Healy Marie Anne, Emerging Nanonisation Technologies: Tailoring Crystalline Versus Amorphous Nanomaterials, Current Topics in Medicinal Chemistry 2015; 15 (22) . https://dx.doi.org/10.2174/1568026615666150605122917
DOI https://dx.doi.org/10.2174/1568026615666150605122917 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Use of Biguanides and the Risk of Colorectal Cancer: A Register-Based Cohort Study
Current Drug Safety ACE2-Ang-(1-7)-Mas Axis in Brain: A Potential Target for Prevention and Treatment of Ischemic Stroke
Current Neuropharmacology Maintenance of Gastrointestinal Glucose Homeostasis by the Gut-Brain Axis
Current Protein & Peptide Science Optimization of Stability Indicating LC Method for the Sensitive In vitro Determination from Solid Lipid Nanoparticles and Ex vivo Analysis from Rat Skin of Etofenamate
Current Pharmaceutical Analysis Omega-3 Fatty Acids: Role in Metabolism and Cardiovascular Disease
Current Pharmaceutical Design Omalizumab for Asthma: Indications, Off-Label Uses and Future Directions
Recent Patents on Inflammation & Allergy Drug Discovery Chondromodulating Chimeric Prodrugs of Diacetylrhein: Synthesis and Evaluation in Monoiodoacetate-induced Hyperalgesia
Medicinal Chemistry An Old Drug with a New Purpose: Cardiovascular Actions of Acetaminophen (Paracetamol)
Current Drug Targets - Cardiovascular & Hematological Disorders Lipid-Induced Modulation of Protective Signalling Pathways in Cardiovascular Disease: The Role of High Density Lipoproteins
Current Signal Transduction Therapy The Relative Transcription Index: A Gene Expression Based Metric for Prioritization of Drug Candidates
Combinatorial Chemistry & High Throughput Screening Biotechnological Production of Taxol and Related Taxoids: Current State and Prospects
Anti-Cancer Agents in Medicinal Chemistry The Potential Effect of Carvedilol Against Osteoporosis in Ovariectomized Rats
Current Drug Therapy Role of the Endosomal ESCRT Machinery in HIV-1 Vpu-Induced Down- Regulation of BST2/Tetherin
Current HIV Research Drug Targeting Based on a New Concept-Targeting Against TLR4 as an Example
Endocrine, Metabolic & Immune Disorders - Drug Targets Prophylactic Vaccine Strategies and the Potential of Therapeutic Vaccines Against Herpes Simplex Virus
Current Pharmaceutical Design Fungal Pathogens Research: Novel and Improved Molecular Approaches for the Discovery of Antifungal Drug Targets
Current Drug Targets Multiple Sclerosis: Current and Future Treatment Options
Endocrine, Metabolic & Immune Disorders - Drug Targets Polyunsaturated Fatty Acids in Pregnancy and Metabolic Syndrome: A Review
Current Pharmaceutical Biotechnology Toll-like Receptor-4: A New Target for Preterm Labour Pharmacotherapies?
Current Pharmaceutical Design Production Technology and Functionality of Bioactive Peptides
Current Pharmaceutical Design